Yiming Angko-B (01541): Phase II clinical trial of IMM2510 combined with IMM27M for first-line treatment of advanced HCC completed first patient administration

According to the Zhitong Finance App, Yiming Angko-B (01541) announced that the phase II clinical trial of IMM2510 (perviraflupe α) combined with IMM27M (tezesubizumab) in first-line treatment of patients with advanced hepatocellular carcinoma (“HCC”) successfully completed the first patient administration. The study aimed to evaluate the initial efficacy and safety of IMM2510 combined with IMM27M in this patient group.

Since the first experimental new drug (“IND”) application for IMM2510 combined with IMM27M was submitted in 2023, clinical development of this combination therapy has progressed steadily and has shown outstanding potential. The phase Ib clinical trial of iMM2510 combined with iMM27M for advanced solid tumors has determined the recommended phase II dose (“RP2D”), and extended studies are currently being conducted on solid tumors (including esophageal squamous cell carcinoma and squamous non-small cell lung cancer) after previous immunotherapy has failed. Preliminary data showed that the combination therapy was generally well tolerated. Of the 6 patients with esophageal squamous cell carcinoma whose efficacy could be assessed during the dose escalation phase, 3 achieved partial remission (“PR”), 2 were in stable condition (“SD”), 1 had no confirmed disease progression by the immune system (“iUPD”), and the objective remission rate (“ORR”) reached 50%. Encouraging early clinical results confirm that IMM2510 combined with IMM27M has significant anti-tumor activity and controlled safety in the treatment of advanced solid tumors.